Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML
Assessment of safety and tolerability of drug combination and determine time on treatment, Overall survival (OS) and response rate with patient disease burden, and type of disease
Acute Myeloid Leukemia
DRUG: ADI-PEG 20|DRUG: Cytarabine
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], through study completion; anticipated to be 2 years
Assessment of safety and tolerability of drug combination and determine time on treatment, Overall survival (OS) and response rate with patient disease burden, and type of disease